

Global Studies for Favipiravir

Row	Saved	Status	Study Title	Conditions	Interventions	Locations
1		Recruiting	Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh	<ul style="list-style-type: none"> COVID-19 Favipiravir (Favipira) 	<ul style="list-style-type: none"> Drug: Favipiravir Drug: Only Standard Treatment 	<ul style="list-style-type: none"> Mahanagar General Hospital, Dhaka (Site-1), Mugda Medical College Hospital, Dhaka (Site-2), Kurmitola General Hospital, Dhaka (Site-3), Dhaka Medical College Hospital, Dhaka (Site-4) Dhaka, Bangladesh
2		Completed	Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19	<ul style="list-style-type: none"> COVID-19 Favipiravir Kaletra (and 2 more...) 	<ul style="list-style-type: none"> Drug: Favipiravir Drug: Hydroxychloroquine Drug: Lopinavir / Ritonavir 	<ul style="list-style-type: none"> Mohammad Sadegh Bagheri Baghdasht Tehran, Iran, Islamic Republic of
3		Completed	A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza	<ul style="list-style-type: none"> Influenza, Human Critical Illness Influenza 	<ul style="list-style-type: none"> Drug: Favipiravir Drug: Oseltamivir 75Mg Capsule 	<ul style="list-style-type: none"> China-Japan Friendship Hospital Beijing, China
4		Recruiting	Favipiravir vs Hydroxychloroquine in COVID-19	<ul style="list-style-type: none"> SARS-CoV 2 COVID-19 	<ul style="list-style-type: none"> Drug: Hydroxychloroquine Drug: Favipiravir Other: Routine care for COVID-19 patients 	<ul style="list-style-type: none"> Royal College of Surgeons in Ireland - Bahrain Manama, Bahrain
5		Recruiting	Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019	<ul style="list-style-type: none"> COVID-19 	<ul style="list-style-type: none"> Drug: Favipiravir Combined With Tocilizumab Drug: Favipiravir Drug: Tocilizumab 	<ul style="list-style-type: none"> Guiqiang Wang Beijing, Beijing, China Peking University First Hospital Beijing, Beijing, China Ezhou Central Hospital Wuhan, Hubei, China (and 3 more...)
6		Not yet recruiting	Favipiravir Therapy in Adults With Mild COVID-19	<ul style="list-style-type: none"> COVID-19 	<ul style="list-style-type: none"> Drug: Favipiravir Drug: Placebo 	
7		Recruiting New	Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients	<ul style="list-style-type: none"> Covid19 	<ul style="list-style-type: none"> Drug: AVIGAN Drug: Placebo Comparator 	<ul style="list-style-type: none"> Jaber Al-Ahmad Al-Sabah Hospital (South Surra) Kuwait City, Kuwait Mishref Field Hospital (Mishref) Kuwait City, Kuwait
8		Not yet recruiting	Favipiravir in Hospitalized COVID-19 Patients	<ul style="list-style-type: none"> COVID-19 	<ul style="list-style-type: none"> Drug: Favipiravir Drug: Hydroxychloroquine 	<ul style="list-style-type: none"> Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services Tehran, Iran, Islamic Republic of
9		Completed	Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment	<ul style="list-style-type: none"> Healthy Hepatic Impairment 	<ul style="list-style-type: none"> Drug: Favipiravir 	<ul style="list-style-type: none"> University of Miami Miami, Florida, United States Orlando Clinical Research Center Orlando, Florida, United States
10		Recruiting	Favipiravir and HydroxyChloroquine Combination Therapy	<ul style="list-style-type: none"> COVID19 	<ul style="list-style-type: none"> Combination Product: Favipiravir and Hydroxychloroquine 	<ul style="list-style-type: none"> King Abdulaziz Hospital - Al Ahsa Hasa, Eastern Region, Saudi Arabia AlMadina General Hospital Al Madinah, Saudi Arabia Al-Qatif Central Hospital Al-Qatif, Saudi Arabia (and 5 more...)
11		Not yet recruiting	Safety and Efficacy of Maraviroc and/or Favipiravir vs Currently Used Therapy in Severe COVID-19 Adults	<ul style="list-style-type: none"> COVID-19 	<ul style="list-style-type: none"> Drug: Maraviroc + Currently used therapy Procedure: Curently used therapy for COVID-19 non-critical patients Drug: Favipiravir + Currently used therapy Drug: Maraviroc+Favipiravir+CT 	<ul style="list-style-type: none"> Hospital General de México "Dr. Eduardo Liceaga" Mexico City, Cdmx, Mexico
12		Terminated	Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen	<ul style="list-style-type: none"> Ebola Virus Survivor 	<ul style="list-style-type: none"> Drug: Favipiravir 	<ul style="list-style-type: none"> Conakry Conakry, Guinea Nzérékoré Nzérékoré, Guinea
13		Completed	Efficacy of Favipiravir Against Severe Ebola Virus Disease	<ul style="list-style-type: none"> Ebola Virus Disease 	<ul style="list-style-type: none"> Other: WHO-recommended therapies Drug: Favipiravir 	
14		Completed	Efficacy and Safety of Favipiravir in Management of COVID-19	<ul style="list-style-type: none"> Coronavirus Disease (COVID-19) 	<ul style="list-style-type: none"> Drug: favipiravir Drug: Standard of care therapy 	<ul style="list-style-type: none"> Faculty of Medicine Ain Shams University Research Institute-Clinical Research Center Cairo, Non-US, Egypt
15		Completed	Efficacy of Favipiravir Against Ebola (JIKI)	<ul style="list-style-type: none"> Ebola Virus Disease 	<ul style="list-style-type: none"> Drug: Favipiravir 	<ul style="list-style-type: none"> The caregivers treatment center Conakry, Guinea MSF Ebola treatment centre Gueckedou, Guinea French Red Cross Ebola care center Macenta, Guinea ALIMA Ebola care center Nzerekore, Guinea
16		Enrolling by invitation	Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19	<ul style="list-style-type: none"> Sars-CoV2 COVID-19 	<ul style="list-style-type: none"> Drug: Favipiravir Drug: Placebo Other: Standard of care treatment 	<ul style="list-style-type: none"> Stanford University Stanford, California, United States

17	Completed	Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults	<ul style="list-style-type: none"> Influenza 	<ul style="list-style-type: none"> Drug: favipiravir Drug: placebo 	<ul style="list-style-type: none"> Birmingham, Alabama, United States Birmingham, Alabama, United States Huntsville, Alabama, United States (and 244 more...)
18	Completed	Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316	<ul style="list-style-type: none"> Influenza 	<ul style="list-style-type: none"> Drug: favipiravir Drug: Placebo 	<ul style="list-style-type: none"> Birmingham, Alabama, United States Birmingham, Alabama, United States Hunstville, Alabama, United States (and 219 more...)
19	Recruiting	Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia	<ul style="list-style-type: none"> Novel Coronavirus Pnuemonia 	<ul style="list-style-type: none"> Drug: favipiravir tablets+chloroquine phosphatetables tablets Drug: Favipiravir tablets Drug: Placebo 	<ul style="list-style-type: none"> Beijing Chaoyang hospital Beijing, Beijing, China
20	Recruiting	Early Intervention in COVID-19: Favipiravir Verses Standard Care	<ul style="list-style-type: none"> Coronavirus Infection 	<ul style="list-style-type: none"> Drug: Favipiravir Other: Standard of care management 	<ul style="list-style-type: none"> Chelsea and Westminster Hospital London, United Kingdom West Middlesex University Hospital London, United Kingdom
21	Not yet recruiting New	FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals	<ul style="list-style-type: none"> COVID-19 	<ul style="list-style-type: none"> Drug: Favipiravir Drug: Lopinavir/ Ritonavir Other: Favipiravir Placebo Other: Lopinavir/ Ritonavir Placebo 	
22	Recruiting	Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age	<ul style="list-style-type: none"> COVID-19 	<ul style="list-style-type: none"> Drug: Favipiravir 	<ul style="list-style-type: none"> Hacettepe University, School of Medicine Ankara, Turkey
23	Active, not recruiting	An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19	<ul style="list-style-type: none"> COVID-19 	<ul style="list-style-type: none"> Drug: Favipiravir Drug: Standard of Care 	<ul style="list-style-type: none"> Republican Clinical Hospital Makhachkala, Russian Federation "K+31" Clinic Moscow, Russian Federation "Khaven" Llc Moscow, Russian Federation (and 19 more...)
24	Active, not recruiting	Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19	<ul style="list-style-type: none"> COVID-19 	<ul style="list-style-type: none"> Drug: Favipiravir Other: Placebo 	<ul style="list-style-type: none"> Asst Fatebenefratelli Sacco Milano, Italy
25	Recruiting	Favipiravir, Protease Inhibitors, Oseltamivir -Gpo, Hydroxychloroquine for Treatment of COVID-19	<ul style="list-style-type: none"> SARS-COV-2 Infections COVID-19 	<ul style="list-style-type: none"> Drug: Oral 	<ul style="list-style-type: none"> Assistant Professor Subsai Kongsangdao Bangkok, Thailand
26	Recruiting	Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19	<ul style="list-style-type: none"> Sars-CoV2 COVID-19 	<ul style="list-style-type: none"> Drug: Favipiravir (3200 mg + 1200 mg) Drug: Favipiravir (3600 mg + 1600 mg) Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine (and 3 more...) 	<ul style="list-style-type: none"> Hacettepe University, School of Medicine Ankara, Turkey
27	Not yet recruiting	A Multi-center.Randomized.Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19	<ul style="list-style-type: none"> COVID-19 	<ul style="list-style-type: none"> Drug: Favipiravir Other: Placebo 	<ul style="list-style-type: none"> The First Affiliated Hospital of Zhejiang University School of Medicine Hangzhou, Shangcheng District, China Peking University First Hospital Beijing, Xicheng District, China Department of Internal Medicine Pneumology and infectious diseases Neukölln Clinic Berlin, Germany (and 7 more...)
28	Recruiting	Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19	<ul style="list-style-type: none"> COVID-19 	<ul style="list-style-type: none"> Drug: Favipiravir + Standard of Care Drug: Standard of Care 	<ul style="list-style-type: none"> HonorHealth Scottsdale, Arizona, United States University of Miami Miller School of Medicine Miami, Florida, United States Boston Medical Center Boston, Massachusetts, United States (and 5 more...)
29	Recruiting	Bioequivalence Study of Favipiravir From Flupirava 200 mg Tablet (European Egyptian Pharmaceutical Industries , Egypt) Versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan)	<ul style="list-style-type: none"> Healthy 	<ul style="list-style-type: none"> Drug: Flupirava Drug: Avigan 	<ul style="list-style-type: none"> Genuine Research Center GRC Cairo, Egypt
30	Completed Has Results	Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza	<ul style="list-style-type: none"> Influenza 	<ul style="list-style-type: none"> Drug: Favipiravir Drug: Placebo comparator 	<ul style="list-style-type: none"> #065 Birmingham, Alabama, United States #156 Huntsville, Alabama, United States #151 Mobile, Alabama, United States (and 225 more...)
31	Completed Has Results	Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions	<ul style="list-style-type: none"> Bioequivalence 	<ul style="list-style-type: none"> Drug: FAVICOVIR 200 mg Film Tablet Drug: AVIGAN 200 mg Film Tablets 	<ul style="list-style-type: none"> Novagenix Drug R&D Center Akyurt, Ankara, Turkey Farmagen Ar-Ge Biyot. Ltd. Sti. Sahinbey, Gaziantep, Turkey
32	Completed Has Results	Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions	<ul style="list-style-type: none"> Bioequivalence 	<ul style="list-style-type: none"> Drug: FAVIRA 200 MG Film Tablet Drug: AVIGAN 200 MG Film Tablets 	<ul style="list-style-type: none"> Novagenix Drug R&D Center Akyurt, Ankara, Turkey Farmagen Ar-Ge Biyot. Ltd. Sti. Sahinbey, Gaziantep, Turkey

33	Completed	Bioequivalence Study of Favipiravir 200 mg Film Tablet (World Medicine, Turkey) Under Fasting Conditions	<ul style="list-style-type: none"> Bioequivalence 	<ul style="list-style-type: none"> Drug: Test: Favipiravir 200 mg (LOQLAR) Drug: Reference: Favipiravir 200 mg (Avigan) 	<ul style="list-style-type: none"> Novagenix Drug R&D Center Akyurt, Ankara, Turkey Farmagen Ar-Ge Biyot. Ltd. Sti. Sahinbey, Gaziantep, Turkey
34	Recruiting	Efficacy of Faviprevir in COVID-19 Treatment	<ul style="list-style-type: none"> COVID 	<ul style="list-style-type: none"> Drug: Favipiravir Drug: Placebos 	<ul style="list-style-type: none"> Tanta University, Ainshams University Tanta, Egypt
35	Completed	T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza	<ul style="list-style-type: none"> Influenza 	<ul style="list-style-type: none"> Drug: Placebo Drug: Favipiravir 	<ul style="list-style-type: none"> Miami Research Associates Miami, Florida, United States
36	Completed	Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions	<ul style="list-style-type: none"> Bioequivalence 	<ul style="list-style-type: none"> Drug: FAVIR 200 MG FT Drug: AVIGAN 200 mg FT 	<ul style="list-style-type: none"> Novagenix Drug R&D Center Akyurt, Ankara, Turkey Farmagen Ar-Ge Biyot. Ltd. Sti. Gaziantep, Turkey
37	Recruiting	Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive	<ul style="list-style-type: none"> COVID-19 	<ul style="list-style-type: none"> Drug: Favipiravir 	<ul style="list-style-type: none"> The Second People's Hospital of Fuyang Fuyang, Anhui, China Ezhou Hospital of Traditional Chinese Medicine Ezhou, Hubei, China Ezhou Central Hospital Wuhan, Hubei, China (and 5 more...)
38	Not yet recruiting	Control of COVID-19 Outbreaks in Long Term Care	<ul style="list-style-type: none"> COVID-19 SARS-CoV-2 	<ul style="list-style-type: none"> Drug: Favipiravir Drug: Favipiravir Placebo 	